BioSpace News Archive

Salubris Biotherapeutics, Inc. today reported new data from Cohort 2 of the ongoing Phase 1 study evaluating JK07, the Company’s lead drug candidate, for the treatment of heart failure with reduced ejection fraction (HFrEF).

AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022.

Concert Pharmaceuticals, Inc. today announced positive topline results from its recently completed Phase 3 clinical trial, THRIVE-AA1.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program.

Aurora Spine Corporation today announced it will issue its financial results press release for the first quarter ended March 31, 2022, on Monday May 23, 2022.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with spinocerebellar ataxia (SCA).

Medison Pharma today announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings plc.

HCW Biologics Inc. announced today that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will give a corporate presentation on May 25, 2022 at the H.C. Wainwright Annual Global Life Sciences Conference.

Shockwave Medical, Inc. and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and sell the Shockwave IVL System with the Shockwave C 2 Coronary IVL Catheters and the Shockwave M 5 and S 4 Peripheral IVL Catheters in China.